Replies to post #6899 on Biotech Values

[DewDiligence]

PFE has four anti-angio compounds in early development for eye disease: three of its own compounds and one acquired from Angiosyn (#msg-5169089). This is in addition to PFE’s participation in Macugen.

Source: PFE webcast in progress.